Tuberculosis vaccines: Time to think about the next generation

Seminars in Immunology

Volumn 25, Issue 2, 2013, Pages 172-181

  Kaufmann, Stefan H E ^a  

^a MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

Author keywords

BCG; Boost; Latency; Prime; Tuberculosis; Vaccination

Indexed keywords

AD 35; AD 35 VACCINE; BACTERIAL VACCINE; BCG VACCINE; GAMMA INTERFERON; HYBRID 1; HYBRID 1 VACCINE; HYBRID 56; HYBRID 56 VACCINE; HYVAC 4; HYVAC 4 VACCINE; ID 93; ID 93 VACCINE; M 72; M 72 VACCINE; MTBVAC 01; MTBVAC 01 VACCINE; RBCG 30; RBCG 30 VACCINE; SUBUNIT VACCINE; TUBERCULIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

BCG VACCINATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ASSESSMENT; CLOSTRIDIUM PERFRINGENS; CROSS PRESENTATION; DELAYED HYPERSENSITIVITY; HELPER CELL; HUMAN; LISTERIA MONOCYTOGENES; MAJOR HISTOCOMPATIBILITY COMPLEX; MICROBIAL ATTENUATION; MIXED INFECTION; MONONUCLEAR PHAGOCYTE; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; MYCOBACTERIUM VACCAE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POST EXPOSURE PROPHYLAXIS; REGULATORY T LYMPHOCYTE; REVIEW; TUBERCULIN TEST; TUBERCULOSIS;

AD35; ADENOVIRUS 35; ADJUVANT SYSTEM; AG85A; ANTIGEN 85A; AS; BACILLE CALMETTE-GUÉRIN; BCG; BOOST; DCS; DELAYED-TYPE HYPERSENSITIVITY; DENDRITIC CELLS; DTH; GLA; GLUCOPYRANOSYL LIPID A; HLY; IFN-Γ; IFN-Γ RELEASE ASSAYS; IGRA; IL; INTERFERON-GAMMA; INTERLEUKIN; LATENCY; LATENT MTB-INFECTION; LISTERIOLYSIN; LTBI; MAITS; MAJOR HISTOCOMPATIBILITY COMPLEX; MHC; MIP; MONONUCLEAR PHAGOCYTES; MPS; MTB; MUCOSAL-ASSOCIATED INVARIANT T CELLS; MYCOBACTERIUM INDICUS PRANII; MYCOBACTERIUM TUBERCULOSIS; NATURAL KILLER; NK; PERFRINGOLYSIN; PEST; PFO; PRIME; PROLINE (P), GLUTAMIC ACID (E), SERINE (S) AND THREONINE (T); REGULATORY T CELLS; TB; TDB; TH1; TLR; TNF; TOLL-LIKE RECEPTOR; TREG CELLS; TREHALOSE 6,6′-DIBEHENATE; TST; TUBERCULIN SKIN TEST; TUBERCULOSIS; TUMOR NECROSIS FACTOR; TYPE 1 HELPER; UREASE C; UREC; VACCINATION;

ADULT; ANIMALS; CHILD; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; HUMANS; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS VACCINES; TUBERCULOSIS, PULMONARY;

EID: 84882276233     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2013.04.006     Document Type: Review

References (112)

1. WHO Global tuberculosis control 2011 2011, World Health Organization, Geneva.
2. Lawn S.D., Zumla A.I. Tuberculosis. Lancet 2011, 378(July (9785)):57-72.
3. Zumla A., Raviglione M., Hafner R., Von Reyn C.F. Tuberculosis. New England Journal of Medicine 2013, 368(February (8)):745-755.
4. Cooper A.M. Cell-mediated immune responses in tuberculosis. Annual Review of Immunology 2009, 27:393-422.
5. Rohde K., Yates R.M., Purdy G.E., Russell D.G. Mycobacterium tuberculosis and the environment within the phagosome. Immunological Reviews 2007, 219:37-54. October.
6. Sturgill-Koszycki S., Schlesinger P.H., Chakraborty P., Haddix P.L., Collins H.L., Fok A.K., et al. Lack of acidification in Mycobacterium phagosomes produced by exclusion of the vesicular proton-ATPase. Science 1994, 263(February (5147)):678-681.
7. Barry C.E., Boshoff H.I., Dartois V., Dick T., Ehrt S., Flynn J., et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nature Reviews Microbiology 2009, 7(December (12)):845-855.
8. Esmail H., Barry C.E., Wilkinson R.J. Understanding latent tuberculosis: the key to improved diagnostic and novel treatment strategies. Drug Discovery Today 2012, 17(May (9,10)):514-521.
9. Gengenbacher M., Kaufmann S.H. Mycobacterium tuberculosis: success through dormancy. FEMS Microbiology Reviews 2012, 36(May (3)):514-532.
10. Young D.B., Gideon H.P., Wilkinson R.J. Eliminating latent tuberculosis. Trends in Microbiology 2009, 17(May (5)):183-188.
11. Betts J.C., Lukey P.T., Robb L.C., McAdam R.A., Duncan K. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Molecular Microbiology 2002, 43(February (3)):717-731.
12. Schnappinger D., Ehrt S., Voskuil M.I., Liu Y., Mangan J.A., Monahan I.M., et al. Transcriptional adaptation of Mycobacterium tuberculosis within macrophages: insights into the phagosomal environment. Journal of Experimental Medicine 2003, 198(September (5)):693-704.
13. Chao M.C., Rubin E.J. Letting sleeping dos lie: does dormancy play a role in tuberculosis?. Annual Review of Microbiology 2010, 64:293-311. October 13.
14. Epstein S.S. Microbial awakenings. Nature 2009, 457(February (7233)):1083.
15. Comstock G.W. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?. International Journal of Tuberculosis and Lung Disease 1999, 3(October (10)):847-850.
16. Smieja M.J., Marchetti C.A., Cook D.J., Smaill F.M. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database of Systematic Reviews 2000, (2):CD001363.
17. Kaufmann S.H. Fact and fiction in tuberculosis vaccine research: 10 years later. The Lancet Infectious Diseases 2011, 11(August (8)):633-640.
18. Kaufmann S.H. Tuberculosis vaccines - a new kid on the block. Nature Medicine 2011, 17(February (2)):159-160.
19. Kaufmann S.H. Tuberculosis vaccine development: strength lies in tenacity. Trends in Immunology 2012, 33(July (7)):373-379.
20. Bertholet S., Ireton G.C., Ordway D.J., Windish H.P., Pine S.O., Kahn M., et al. A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis. Science Translational Medicine 2010, 2(October (53)):53ra74.
21. Aagaard C., Hoang T., Dietrich J., Cardona P.J., Izzo A., Dolganov G., et al. A multistage tuberculosis vaccine that confers efficient protection pre- and post-exposure. Nature Medicine 2011, 17(2):189-194.
22. Dorhoi A., Kaufmann S.H. Fine-tuning of T cell responses during infection. Current Opinion in Immunology 2009, 21(August (4)):367-377.
23. Reece S.T., Kaufmann S.H. Floating between the poles of pathology and protection: can we pin down the granuloma in tuberculosis?. Current Opinion in Microbiology 2012, 15(February (1)):63-70.
24. Dorhoi A., Reece S.T., Kaufmann S.H.E. Immunity to intracellular bacteria. Fundamental immunology 2012, 973-1000. Wolters Kluwer Health, Lippincott Williams, Wilkins, Philadelphia. 7th ed. W.E. Paul (Ed.).
25. Ottenhoff T.H., Lewinsohn DALD.M. Human CD4 and CD8 T cell responses to Mycobacterium tuberculosis: antigen specificity, function, implications and applications. Handbook of tuberculosis: immunology and cell biology 2008, 119-156. Weinheim, Germany, Wiley-VCH Verlag. S.H.E. Kaufmann, W.J. Britton (Eds.).
26. Khader S.A., Bell G.K., Pearl J.E., Fountain J.J., Rangel-Moreno J., Cilley G.E., et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4(+) T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nature Immunology 2007, 8(April (4)):369-377.
27. Desel C., Dorhoi A., Bandermann S., Grode L., Eisele B., Kaufmann S.H. Recombinant BCG {Delta}ureC hly+ induces superior protection over parental BCG by stimulating a balanced combination of type 1 and type 17 cytokine responses. Journal of Infectious Diseases 2011, 204(September (10)):1573-1584.
28. Cruz A., Fraga A.G., Fountain J.J., Rangel-Moreno J., Torrado E., Saraiva M., et al. Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection with Mycobacterium tuberculosis. Journal of Experimental Medicine 2010, 207(August (8)):1609-1616.
29. Auffray C., Sieweke M.H., Geissmann F. Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annual Review of Immunology 2009, 27:669-692.
30. Chowdhury D., Lieberman J. Death by a thousand cuts: granzyme pathways of programmed cell death. Annual Review of Immunology 2008, 26:389-420.
31. Nathan C. Neutrophils and immunity: challenges and opportunities. Nature Reviews Immunology 2006, 6(March (3)):173-182.
32. Kaufmann S.H. Future vaccination strategies against tuberculosis: thinking outside the box. Immunity 2010, 33(October (4)):567-577.
33. Mosmann T.R., Coffman R.L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annual Review of Immunology 1989, 7:145-173.
34. Romagnani S. Cytokines. Immunology 2005, 273-299. Hodder Arnold/ASM Press, London/Washington, D.C. 10th ed. S.H.E. Kaufmann, M.W. Steward (Eds.).
35. Harding C.V., Boom W.H. Regulation of antigen presentation by Mycobacterium tuberculosis: a role for toll-like receptors. Nature Reviews Microbiology 2010, 8(April (4)):296-307.
36. Kaufmann S.H.E. Immunity to intracellular bacteria. Fundamental immunology 2003, 1229-1261. Lippincott-Raven, Philadelphia, NY. 5th ed. W.E. Paul (Ed.).
37. Stenger S., Hanson D.A., Teitelbaum R., Dewan P., Niazi K.R., Froelich C.J., et al. An antimicrobial activity of cytolytic T cells mediated by granulysin. Science 1998, 282(October (5386)):121-125.
38. van der Wel N., Hava D., Houben D., Fluitsma D., van Z.M., Pierson J., et al. M. tuberculosis and M. leprae translocate from the phagolysosome to the cytosol in myeloid cells. Cell 2007, 129(June (7)):1287-1298.
39. Schaible U.E., Winau F., Sieling P.A., Fischer K., Collins H.L., Hagens K., et al. Apoptosis facilitates antigen presentation to T lymphocytes through MHC-I and CD1 in tuberculosis. Nature Medicine 2003, 9(8):1039-1046.
40. Winau F., Weber S., Sad S., de Diego J., Hoops S.L., Breiden B., et al. Apoptotic vesicles crossprime CD8 T cells and protect against tuberculosis. Immunity 2006, 24(January (1)):105-117.
41. Joosten S.A., Ottenhoff T.H. Human CD4 and CD8 regulatory T cells in infectious diseases and vaccination. Human Immunology 2008, 69(November (11)):760-770.
42. Urdahl K.B., Shafiani S., Ernst J.D. Initiation and regulation of T-cell responses in tuberculosis. Mucosal Immunology 2011, 4(May (3)):288-293.
43. Keir M.E., Butte M.J., Freeman G.J., Sharpe A.H. PD-1 and its ligands in tolerance and immunity. Annual Review of Immunology 2008, 26:677-704.
44. De Libero G., Mori L. Recognition of lipid antigens by T cells. Nature Reviews Immunology 2005, 5(June (6)):485-496.
45. Gold M.C., Cerri S., Smyk-Pearson S., Cansler M.E., Vogt T.M., Delepine J., et al. Human mucosal associated invariant T cells detect bacterially infected cells. PLoS Biology 2010, 8(6):e1000407.
46. Scotet E., Nedellec S., Devilder M.C., Allain S., Bonneville M. Bridging innate and adaptive immunity through gammadelta T-dendritic cell crosstalk. Frontiers in Bioscience 2008, 13:6872-6885.
47. Harries A.D., Zachariah R., Corbett E.L., Lawn S.D., Santos-Filho E.T., Chimzizi R., et al. The HIV-associated tuberculosis epidemic - when will we act?. Lancet 2010, 375(May (9729)):1906-1919.
48. Kline S.E., Hedemark L.L., Davies S.F. Outbreak of tuberculosis among regular patrons of a neighborhood bar. New England Journal of Medicine 1995, 333(July (4)):222-227.
49. Mahan C.S., Zalwango S., Thiel B.A., Malone L.L., Chervenak K.A., Baseke J., et al. Innate and adaptive immune responses during acute M. tuberculosis infection in adult household contacts in Kampala, Uganda. The American Journal of Tropical Medicine and Hygine 2012, 86(April (4)):690-697.
50. Houk V.N. Spread of tuberculosis via recirculated air in a naval vessel: the Byrd study. Annals of the New York Academy of Sciences 1980, 353:10-24.
51. Diel R., Goletti D., Ferrara G., Bothamley G., Cirillo D., Kampmann B., et al. Interferon-gamma release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. European Respiratory Journal 2011, 37(January (1)):88-99.
52. Simeone R., Bottai D., Brosch R. ESX/type VII secretion systems and their role in host-pathogen interaction. Current Opinion in Microbiology 2009, 12(February (1)):4-10.
53. Ewer K., Millington K.A., Deeks J.J., Alvarez L., Bryant G., Lalvani A. Dynamic antigen-specific T-cell responses after point-source exposure to Mycobacterium tuberculosis. American Journal of Respiratory and Critical Care Medicine 2006, 174(October (7)):831-839.
54. Ulrichs T., Kaufmann S.H.E. New insights into the function of granulomas in human tuberculosis. Journal of Pathology 2006, 208(January (2)):261-269.
55. Day T.A., Koch M., Nouailles G., Jacobsen M., Kosmiadi G.A., Miekley D., et al. Secondary lymphoid organs are dispensable for the development of T-cell-mediated immunity during tuberculosis. European Journal of Immunology 2010, March 10.
56. Calmette A., Guérin C., Boquet A., Négre L. La vaccination préventive contre la tuberculose par le "BCG" 1927, Masson, Paris.
57. Kaufmann S.H., Hussey G., Lambert P.H. New vaccines for tuberculosis. Lancet 2010, 375(June (9731)):2110-2119.
58. Colditz G.A., Brewer T.F., Berkey C.S., Wilson M.E., Burdick E., Fineberg H.V., et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. The Journal of American Medical Association 1994, 271(March (9)):698-702.
59. Soysal A., Millington K.A., Bakir M., Dosanjh D., Aslan Y., Deeks J.J., et al. Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study. Lancet 2005, 366(October (9495)):1443-1451.
60. Benevolo-de-Andrade T.C., Monteiro-Maia R., Cosgrove C., Castello-Branco L.R. BCG Moreau Rio de Janeiro: an oral vaccine against tuberculosis - review. Memorias do Instituto Oswaldo Cruz 2005, 100(August (5)):459-465.
61. Kaufmann S.H., Gengenbacher M. Recombinant live vaccine candidates against tuberculosis. Current Opinion in Biotechnology 2012, 23(April (6)):900-907.
62. Abou-Zeid C., Ratliff T.L., Wiker H.G., Harboe M., Bennedsen J., Rook G.A. Characterization of fibronectin-binding antigens released by Mycobacterium tuberculosis and Mycobacterium bovis BCG. Infection and Immunity 1988, 56(December (12)):3046-3051.
63. Belisle J.T., Vissa V.D., Sievert T., Takayama K., Brennan P.J., Besra G.S. Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis. Science 1997, 276(May (5317)):1420-1422.
64. Horwitz M.A., Harth G., Dillon B.J., Maslesa-Galic S. Recombinant bacillus Calmette-Guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proceedings of the National Academy of Sciences of the United States of America 2000, 97(25):13853-13858.
65. Grode L., Seiler P., Baumann S., Hess J., Brinkmann V., Nasser Eddine A., et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin. Journal of Clinical Investigation 2005, 115(9):2472-2479.
66. Bavdek A., Kostanjsek R., Antonini V., Lakey J.H., Dalla S.M., Gilbert R.J., et al. pH dependence of listeriolysin O aggregation and pore-forming ability. FASEB Journal 2012, 279(January (1)):126-141.
67. Farinacci M., Weber S., Kaufmann S.H.E. The recombinant tuberculosis vaccine rBCG δureC:: hly+ induces apoptotic vescicles for improved priming of CD4+ and CD8+ T cells. Vaccine 2012, 30(7608):7614.
68. Decatur A.L., Portnoy D.A. A PEST-like sequence in listeriolysin O essential for Listeria monocytogenes pathogenicity. Science 2000, 290(November (5493)):992-995.
69. Palmer M. The family of thiol-activated, cholesterol-binding cytolysins. Toxicon 2001, 39(November (11)):1681-1689.
70. Sun R., Skeiky Y.A., Izzo A., Dheenadhayalan V., Imam Z., Penn E., et al. Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis. Vaccine 2009, 27(July (33)):4412-4423.
71. Mollenkopf H.J., Grode L., Mattow J., Stein M., Mann P., Knapp B., et al. Application of mycobacterial proteomics to vaccine design: improved protection by Mycobacterium bovis BCG prime-Rv3407 DNA boost vaccination against tuberculosis. Infection and Immunity 2004, 72(November (11)):6471-6479.
72. Kupferschmidt K. Infectious disease. Taking a new shot at a TB vaccine. Science 2011, 334(December (6062)):1488-1490.
73. TBVI. Financial support for two vaccine candidates. 14.01.13. http://www.tbvi.eu/news-agenda/news/news-message/financial-support-for-two-vaccine-candidates.html.
74. Von Eschen K., Morrison R., Braun M., Ofori-Anyinam O., De Kock E., Pavithran P., et al. The candidate tuberculosis vaccine Mtb72F/AS02A: tolerability and immunogenicity in humans. Human Vaccines 2009, 5(7):475-482.
75. Skjot R.L., Brock I., Arend S.M., Munk M.E., Theisen M., Ottenhoff T.H., et al. Epitope mapping of the immunodominant antigen TB10.4 and the two homologous proteins TB10.3 and TB12.9, which constitute a subfamily of the esat-6 gene family. Infection and Immunity 2002, 70(October (10)):5446-5453.
76. Dietrich J., Aagaard C., Leah R., Olsen A.W., Stryhn A., Doherty T.M., et al. Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. Journal of Immunology 2005, 174(May (10)):6332-6339.
77. Lingnau K., Riedl K., von Gabain A. IC31 and IC30, novel types of vaccine adjuvant based on peptide delivery systems. Expert Review of Vaccines 2007, 6(October (5)):741-746.
78. Agger E.M., Rosenkrands I., Hansen J., Brahimi K., Vandahl B.S., Aagaard C., et al. Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PLoS One 2008, 3(9):e3116.
79. Christensen D., Foged C., Rosenkrands I., Lundberg C.V., Andersen P., Agger E.M., et al. CAF01 liposomes as a mucosal vaccine adjuvant: in vitro and in vivo investigations. International Journal of Pharmaceutics 2010, 390(May (1)):19-24.
80. McShane H., Pathan A.A., Sander C.R., Keating S.M., Gilbert S.C., Huygen K., et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nature Medicine 2004, 10(November (11)):1240-1244.
81. Tameris M.D., Hatherill M., Landry B.S., Scriba T.J., Snowden M.A., Lockhart S., et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 2013, February 1. 10.1016/S0140-6736(13)60177-4.
82. Radosevic K., Wieland C.W., Rodriguez A., Weverling G.J., Mintardjo R., Gillissen G., et al. Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon. Infection and Immunity 2007, 75(August (8)):4105-4115.
83. Santosuosso M., McCormick S., Zhang X., Zganiacz A., Xing Z. Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis. Infection and Immunity 2006, 74(August (8)):4634-4643.
84. Lin P.L., Dietrich J., Tan E., Abalos R.M., Burgos J., Bigbee C., et al. The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection. Journal of Clinical Investigation 2012, 122(January (1)):303-314.
85. Kaufmann S.H., Winau F. From bacteriology to immunology: the dualism of specificity. Nature Immunology 2005, 6(November (11)):1063-1066.
86. Amtliche Berichte Die Wirksamkeit des Koch'schen Heilmittels gegen Tuberkulose 1891, Verlag von Julius Springer, Berlin.
87. Von Reyn C.F., Mtei L., Arbeit R., Waddell R., Cole B., Mackenzie T., et al. Prevention of tuberculosis in Bacille Calmette-Guérin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. Aids 2010, 24(5):675-685.
88. Yang X.Y., Chen Q.F., Li Y.P., Wu S.M. Mycobacterium vaccae as adjuvant therapy to anti-tuberculosis chemotherapy in never-treated tuberculosis patients: a meta-analysis. PLoS One 2011, 6(9):e23826.
89. Gupta A., Ahmad F.J., Ahmad F., Gupta U.D., Natarajan M., Katoch V., et al. Efficacy of Mycobacterium indicus pranii immunotherapy as an adjunct to chemotherapy for tuberculosis and underlying immune responses in the lung. PLoS One 2012, 7(7):e39215.
90. Cardona P.J. RUTI: a new chance to shorten the treatment of latent tuberculosis infection. Tuberculosis (Edinburgh, Scotland) 2006, 86(May (3,4)):273-289.
91. Vilaplana C., Montane E., Pinto S., Barriocanal A.M., Domenech G., Torres F., et al. Double-blind, randomized, placebo-controlled phase I clinical trial of the therapeutical antituberculous vaccine RUTI((R)). Vaccine 2009, 28(October (4)):1106-1116.
92. Gray J.M., Cohn D.L. Tuberculosis and HIV coinfection. Seminars in Respiratory and Critical Care Medicine 2013, 34(February (1)):32-43.
93. Elias D., Britton S., Kassu A., Akuffo H. Chronic helminth infections may negatively influence immunity against tuberculosis and other diseases of public health importance. Expert Review of Anti-infective Therapy 2007, 5(June (3)):475-484.
94. Hesseling A.C., Marais B.J., Gie R.P., Schaaf H.S., Fine P.E., Godfrey-Faussett P., et al. The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children. Vaccine 2007, 25(January (1)):14-18.
95. Guleria I., Teitelbaum R., McAdam R.A., Kalpana G., Jacobs W.R., Bloom B.R. Auxotrophic vaccines for tuberculosis. Nature Medicine 1996, 2(March (3)):334-337.
96. StopTB Partnership, WHO. The Global Plan to Stop TB 2011-2015., 2011. http://www.stoptb.org/assets/documents/global/plan/TB_GlobalPlanToStopTB2011-2015.pdf.
97. Maertzdorf J., Weiner I.J., Kaufmann S.H. Enabling biomarkers for tuberculosis control. International Journal of Tuberculosis and Lung Disease 2012, 16(September (9)):1140-1148.
98. Martin C., Williams A., Hernandez-Pando R., Cardona P.J., Gormley E., Bordat Y., et al. The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs. Vaccine 2006, 24(April (17)):3408-3419.
99. Rouanet C., Debrie A.S., Lecher S., Locht C. Subcutaneous boosting with heparin binding haemagglutinin increases BCG-induced protection against tuberculosis. Microbes and Infection 2009, 11(November (13)):995-1001.
100. Sweeney K.A., Dao D.N., Goldberg M.F., Hsu T., Venkataswamy M.M., Henao-Tamayo M., et al. A recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosis. Nature Medicine 2011, 17(September (10)):1261-1268.
101. Keane J., Gershon S., Wise R.P., Mirabile-Levens E., Kasznica J., Schwieterman W.D., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. New England Journal of Medicine 2001, 345(October (15)):1098-1104.
102. Casadevall A., Pirofski L.A. A new synthesis for antibody-mediated immunity. Nature Immunology 2012, 13(January (1)):21-28.
103. Maglione P.J., Chan J. How B cells shape the immune response against Mycobacterium tuberculosis. European Journal of Immunology 2009, 39(March (3)):676-686.
104. Manz R.A., Hauser A.E., Hiepe F., Radbruch A. Maintenance of serum antibody levels. Annual Review of Immunology 2005, 23:367-386.
105. Amulic B., Cazalet C., Hayes G.L., Metzler K.D., Zychlinsky A. Neutrophil function: from mechanisms to disease. Annual Review of Immunology 2012, 30:459-489.
106. Di Santo J.P. Natural killer cell developmental pathways: a question of balance. Annual Review of Immunology 2006, 24:257-286.
107. Dorhoi A., Reece S.T., Kaufmann S.H. For better or for worse: the immune response against Mycobacterium tuberculosis balances pathology and protection. Immunological Reviews 2011, 240(March (1)):235-251.
108. Mizgerd J.P. Lung infection - a public health priority. PLoS Medicine 2006, 3(February (2)):e76.
109. Doerschuk C.M. Mechanisms of leukocyte sequestration in inflamed lungs. Microcirculation 2001, 8(April (2)):71-88.
110. Weiner J., Maertzdorf J., Kaufmann S.H. The dual role of biomarkers for understanding basic principles and devising novel intervention strategies in tuberculosis. Annals of the New York Academy of Sciences 2012 Nov 26, November 26.
111. Rappuoli R., Aderem A. A 2020 vision for vaccines against HIV, tuberculosis and malaria. Nature 2011, 473(May (7348)):463-469.
112. Querec T.D., Akondy R.S., Lee E.K., Cao W., Nakaya H.I., Teuwen D., et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nature Immunology 2009, 10(January (1)):116-125.